Exelixis Inc (EXEL)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$40.50
Buy
$41.47
$-0.51 (-1.23%)
Prices updated at 13 Dec 2025, 00:52 EST
| Prices minimum 15 mins delay
Prices in USD
Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | 96.49 |
| 2023 | 96.04 |
| 2022 | 96.41 |
| 2021 | 96.32 |
| 2020 | 96.33 |
| 2019 | 96.58 |
| 2018 | 96.91 |
| 2017 | 96.67 |
| 2016 | 96.58 |
| 2015 | 89.52 |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | 5.11 |
| 2024 | 4.82 |
| 2023 | 4.39 |
| 2022 | 3.17 |
| 2021 | 4.69 |
| 2020 | 6.64 |
| 2019 | 5.79 |
| 2018 | 8.27 |
| 2017 | 22.67 |
| 2016 | 28.35 |
| 2015 | 32.82 |
Price/Forward earnings (YTD)
14.14
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | 17.70 |
| 2023 | 6.91 |
| 2022 | 6.41 |
| 2021 | 9.72 |
| 2020 | 5.56 |
| 2019 | 19.41 |
| 2018 | 66.43 |
| 2017 | 24.60 |
| 2016 | -15.13 |
| 2015 | -49.34 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 1.31 |
| 2023 | 1.30 |
| 2022 | 1.23 |
| 2021 | 1.18 |
| 2020 | 1.14 |
| 2019 | 1.12 |
| 2018 | 1.10 |
| 2017 | 2.30 |
| 2016 | 6.67 |
| 2015 | - |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
